« Back
Home /
Tat-NR2B9c (TFA)

Tat-NR2B9c (TFA)

Item no.	HY-P0117A-25mg
Manufacturer	MedChem Express
CASRN	1834571-04-8
Amount	25 mg
Quantity options	10 mM x 1 mL 10 mg 1 mg 25 mg 5 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	99.67
Citations	[1]Cui H, et al. PDZ protein interactions underlying NMDA receptor-mediated excitotoxicity and neuroprotection by PSD-95 inhibitors. J Neurosci. 2007 Sep 12;27(37):9901-15.\|[2]Fan J, et al. P38 MAPK is involved in enhanced NMDA receptor-dependent excitotoxicity in YAC transgenic mouse model of Huntington disease. Neurobiol Dis. 2012 Mar;45(3):999-1009. Behav Brain Res. 7 January 2022, 113537.\|Biochem Biophys Res Commun. 2024 May 8:720:150076.\|J Cereb Blood Flow Metab. 2019 Aug;39(8):1588-1601. \|J Neuropathol Exp Neurol. 2020 Jul 1;79(7):800-808.\|Neuropharmacology. 2024 Mar 21:109905.\|Neuroreport. 2021 Sep 8;32(13):1122-1127.\|PLoS One. 2020 Mar 3;15(3):e0229499. \|Sci Rep. 2018 May 18;8(1):7848.
Smiles	O=C(NCC(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCC(N)=O)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCCN)C(N[C@@H](CC(C)C)C(N[C@@H](CO)C(N[C@@H](CO)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CCC(O)=O)C(N[C@@H](CO)C(N[C@@H](CC(O)=O)C(N[C@@H](C(C)C)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](CC1=CC=C(C=C1)O)N.OC(C(F)(F)F)=O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	Tat-NR2Bct (TFA),NA-1 (TFA)
Shipping Condition	Cool pack
Available
Manufacturer - Type	Peptides
Manufacturer - Applications	Neuroscience-Neurodegeneration
Manufacturer - Targets	iGluR; NO Synthase
Shipping Temperature	Blue Ice
Storage Conditions	-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)
Molecular Weight	2632.90
Product Description	Tat-NR2B9c TFA (Tat-NR2Bct TFA) is a postsynaptic density-95 (PSD-95) inhibitor, with EC50 values of 6.7 nM and 670 nM for PSD-95d2 (PSD-95 PDZ domain 2) and PSD-95d1, respectively. Tat-NR2B9c TFA disrupts the PSD-95/NMDAR interaction, inhibiting NR2A and NR2B binding to PSD-95 with IC50 values of 0.5 μM and 8 μM, respectively. Tat-NR2B9c TFA also inhibits neuronal nitric oxide synthase (nNOS)/PSD-95 interaction, and possesses neuroprotective efficacy[1].
Manufacturer - Research Area	Neurological Disease
Solubility	H2O: ≥ 50 mg/mL
Manufacturer - Pathway	Immunology/Inflammation; Membrane Transporter/Ion Channel; Neuronal Signaling
Isoform	NMDA Receptor; nNOS
Clinical information	No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-P0117A-25mg-safety-datasheet.pdf